Celgene files potential blockbuster luspaterceptCelgene and Acceleron Pharma have submitted their blood disorder drug luspatercept for approval with the FDA, setting up Share XCelgene files potential blockbuster luspatercepthttps://pharmaphorum.com/news/celgene-files-potential-blockbuster-luspatercept/
Celgene-BMS merger looks good to go as shareholder backs downBristol-Myers Squibb’s mega-merger with Celgene looks set to go ahead after activist hedge fund Starboard Value backed out Share XCelgene-BMS merger looks good to go as shareholder backs downhttps://pharmaphorum.com/news/celgene-bms-merger-looks-good-to-go-as-shareholder-backs-down/
MS drug market heats up as FDA backs Novartis’ new pillThe FDA has approved Novartis’ Mayzent (siponimod) multiple sclerosis pill for relapsing forms of the disease, dealing a Share XMS drug market heats up as FDA backs Novartis’ new pillhttps://pharmaphorum.com/news/ms-drug-market-heats-up-as-fda-backs-novartis-new-pill/
Celgene refiles potential MS blockbuster ozanimod with FDACelgene has filed its highly anticipated oral MS drug ozanimod with the US regulator, more than a year Share XCelgene refiles potential MS blockbuster ozanimod with FDAhttps://pharmaphorum.com/news/celgene-refiles-potential-ms-blockbuster-ozanimod-with-fda/
AI drug R&D company Exscientia signs deal with CelgeneUK artificial intelligence (AI) drug discovery company Exscientia has agreed a three year drug discovery deal with Celgene, Share XAI drug R&D company Exscientia signs deal with Celgenehttps://pharmaphorum.com/news/ai-drug-rd-company-exscientia-signs-deal-with-celgene/
Celgene gets US patent let-off ahead of BMS mergerShares in Celgene ticked up yesterday after a let-off in a US court case challenging the patents on Share XCelgene gets US patent let-off ahead of BMS mergerhttps://pharmaphorum.com/news/celgene-gets-us-patent-let-off-ahead-of-bms-merger/
Oncology round-up: Shareholders question BMS/Celgene merger, while Merck & Co’s Keytruda keeps getting strongerWill it happen or not? There are doubts about whether the proposed $74 billion merger of cancer drug Share XOncology round-up: Shareholders question BMS/Celgene merger, while Merck & Co’s Keytruda keeps getting strongerhttps://pharmaphorum.com/views-analysis-oncology/oncology-round-up-shareholders-question-bms-celgene-merger-while-merck-cos-keytruda-keeps-getting-stronger/
Doubts over BMS-Celgene merger after Starboard interventionDoubts are mounting about whether Bristol-Myers Squibb’s $74 billion merger with Celgene will go ahead after another key Share XDoubts over BMS-Celgene merger after Starboard interventionhttps://pharmaphorum.com/news/doubts-over-bms-celgene-merger-after-starboard-intervention/
Largest BMS shareholder opposes Celgene dealBristol-Myers Squibb’s (BMS) largest shareholder has come out against the company’s planned merger with Celgene, putting the future Share XLargest BMS shareholder opposes Celgene dealhttps://pharmaphorum.com/news/largest-bms-shareholder-opposes-celgene-deal/
